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Abstract
Background & Aims—The nonstructural 5A (NS5A) protein of hepatitis C virus (HCV), plays
a critical role in HCV replication and is an attractive target for the therapy of HCV infection. So
far, little is known about the post-translational regulation of NS5A protein and its precise role in
HCV RNA replication. Our objectives were to elucidate the down-regulation of NS5A protein and
HCV RNA replication by zinc mesoporphyrin (ZnMP), and the mechanism by which this process
occurs.
Methods—Human hepatoma cells expressing HCV proteins were used to investigate the post-
translational regulation of ZnMP on NS5A protein by Western blots (WB) and
immunoprecipitation (IP). Quantitative RT-PCR (qRT-PCR) was used to determine the effects of
ZnMP on HCV RNA replication.
Results—ZnMP selectively and markedly down-regulated NS5A protein levels by increasing
degradation of NS5A protein [half life fell from 18.7 h to 2.7 h]. The proteasome inhibitors,
epoxomicin and MG132, significantly abrogated degradation of NS5A protein by ZnMP without
affecting levels of NS5A in the absence of ZnMP. Analysis of immunoprecipitates with an anti-
ubiquitin antibody revealed polyubiquitination of NS5A, suggesting that ZnMP induces
ubiquitination of NS5A protein. In addition, 10 μM of ZnMP reduced HCV replication by ~63%
in the Con1 replicon cells, ~70% in J6/JFH1 HCV transfected cells, and ~90% in J6/JFH1 HCV
infected cells without affecting cell viability.
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Conclusions—ZnMP produces a rapid and profound down-regulation of the NS5A protein by
enhancing its polyubiquitination and proteasome-dependent catabolism. Zinc mesoporphyrin may
hold promise as a novel agent to treat HCV infection.
INTRODUCTION
Hepatitis C virus (HCV) is a major cause of acute hepatitis and chronic liver disease,
including cirrhosis and liver cancer1. Current treatments for HCV infection using pegylated
interferon (Peg-IFN) and ribavirin (RBV) fail to produce sustained virological responses in
fewer than 50% of adequately treated patients infected with HCV genotype 1, and have
numerous unpleasant side effects. These side-effects and the rather high costs, and required
duration of such treatment limit its use. Thus, it is too costly for most patients in developing
countries and many in developed countries to afford. Clearly, more effective strategies to
treat HCV infection are urgently needed.
The hepatitis C virion contains a 9.6-kb positive single-strand RNA genome which encodes
a single polyprotein of approximately 3010 amino acids, that is then processed into
structural (C, E1, E2) and nonstructural (NS2, NS3, NS4A, NS4B, NS5A and NS5B)
proteins2–5. The nonstructural 5A (NS5A) protein, a major component of HCV proteins, is
a 447-amino-acid phosphorylated zinc-metalloprotein with largely unknown functions6, 7.
Recent evidence has shown that NS5A plays a critical role in the replication of HCV, both
directly, with regard to viral RNA replication, and indirectly, by modulating the host cell
environment to favor the virus6–8. NS5A has been shown to interact with nonstructural 5B
(NS5B) protein, the viral RNA-dependent RNA polymerase, and this interaction is essential
for maintenance of subgenomic replications in Huh-7 replicon cells9, 10. NS5A binds to the
3′-ends of HCV positive strand RNA with high affinity, and this binding is essential for
genome replication and infection11. A recent study revealed that a cellular microRNA-196
(miR-196) directly targets NS5A and is able to substantially attenuate viral replication in
JFH1 replicon Huh-7 cells12. The most recent study from Hughes et al reported that domain
III of NS5A is implicated in both RNA replication and assembly of hepatitis C virus
particles in JFH1-infected cells13. Although precise functions of NS5A in both HCV
genomic RNA replication and modulation of physiology of the host cell remain unclear,
targeting NS5A is an attractive emerging strategy for the therapy of HCV infection8, 14.
Zinc mesoporphyrin (ZnMP) is a non-heme metalloporphyrin and a synthetic heme analogue
with a central zinc of the mesoporphyin macrocycle. ZnMP has been demonstrated as a
potent inhibitor of heme oxygenase (HO) and proposed as a therapeutic agent for severe
unconjugated hyperbilirubinemia (e.g., Crigler-Najjar syndrome type II) and for prolonging
effects of heme in therapy of acute porphyric syndromes15, 16. Recent studies from our and
other laboratories have shown that ZnMP17, tin mesoporphyrin (SnMP)18 and heme19
induce ubiquitination and proteasomal degradation of Bach1, a transcriptional repressor of
the heme oxygenase 1 (HO-1) gene, in human hepatoma cells and NIH3T3 cells as one of
the mechanisms by which the HO-1 gene is up-regulated. In addition, we have recently
reported that cobalt protoporphyrin (CoPP) down-regulates HCV core protein and
suppresses HCV replication in human hepatoma cells stably expressing HCV proteins20. So
far, little is known about the ubiquitin-proteasome degradation of NS5A protein and its role
in HCV RNA replication. In this study, we show down-regulation of NS5A protein by
ZnMP and the molecular mechanism involved in this process. We demonstrate that ZnMP
decreases the level of NS5A protein at the post-translational level by modulating protein
degradation through a proteasome-ubiquitin degradation pathway. In addition, ZnMP
suppress HCV RNA replication. We propose that zinc porphyrin-mediated ubiquitin-
proteasome degradation pathway may play a role in affecting the HCV RNA replication
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through controlling the amount of NS5A protein. The observations presented herein suggest
that zinc porphyrins may be of value in treatment of HCV infection.
MATERIALS AND METHODS
See Supplemental Materials and Methods for more details.
Cell Lines
The 9–13, CNS3 and Huh-7/T7 cell lines were kindly provided by R. Bartenschlager
(University of Heidelberg, Heidelberg, Germany). 9–13 subgenomic replicon cells,
containing a replicating HCV nonstructural region of the Con1 isolate, stably express HCV
NS3 to NS5B21. CNS3 cells stably express HCV core to NS3. Huh-7/T7 cells constitutively
express the bacteriophage T7 RNA polymerase22. Cell line Huh-7.5, a highly permissive,
alpha interferon-cured Huh-7 derivative was kindly provided by C. M. Rice (The
Rockefeller University, New York, NY). The Con1 genotype 1b HCV replicon cell line was
from Apath LLC (St, Louis, MO). The Con1 cell line is a Huh-7.5 cell population containing
the full-length HCV genotype 1b replicon 23, 24.
Constructs and Transfection
The pFK-Con1/GDD and pFK-Con1/GND constructs (genotype 1b) were kind gifts of Dr.
R. Bartenschlager (University of Heidelberg, Heidelberg, Germany). The pFK-Con1/GDD
construct containing the wild type Con1 genome was described21 and pFK-Con1/GND
construct was a replication-deficient variant of pFK-Con1/GDD with a single amino
substitution, which changed the GDD motif of the NS5B polymerase active site to GND25.
Transfection of pFK-Con1/GDD or pFK-Con1/GND was performed as described in Suppl.
Materials and Methods.
In Vitro Transcription, HCV RNA Transfection and Infection
The HCV infectious clone pJ6/JFH1 was generously provided by Dr. C. Rice (the
Rockefelller University, New York, NY). The full-length chimeric genome was constructed
with the use of the core-NS2 gene regions from the infectious J6 (genotype 2a) and NS3-
NS5B gene regions from the infectious JFH1 (genotype 2a) as described by Lindenbach et
al23. To generate HCV J6/JFH1 RNA, the pJ6/JFH1 plasmid was linearized with XbaI, and
purified by ethanol precipitation, digestion with proteinase K, and phenol-chloroform
extraction. The linearized plasmid was used as a template for in vitro transcription using the
MEGAscript T7 kit (Ambion, Austin, TX). For HCV RNA transfection, Huh-7.5 cells were
plated in 24-well plates one day prior to transfection and transfected at 70~80% confluence.
Cells were transfected at an RNA/lipofectamine ratio of 1:2 by using 2 μg/well of HCV
RNA and 4 uL/well Lipofectamine 2000 (Invitrogen, Carlsbad, CA) for 48 h. For HCV
infection, cell culture supernatants from the cells transfected with HCV RNA for 48 h were
collected and filtered through a 0.20 μm filter, and infected naïve Huh-7.5 cells in 24-well
plates for 72 h. Total RNA and protein were extracted for subsequent RT-PCR and Western
blot measurements.
Western Blots, Quantitative RT-PCR and Immunoprecipitation (IP)
Western blot analysis and quantitative RT-PCR were performed using the standard protocols
of our laboratory as described previously17. Immunoprecipitation was carried out according
to the manufacturer’s protocol from Santa Cruz (Santa Cruz, CA). Antibodies used are
described in Supplemental Material and Methods.
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9–13 cells were incubated with 100 ug/mL cycloheximide (CHX) in the presence or absence
of 10 uM ZnMP. Western blots were performed using anti-HCV NS5A and anti-GAPDH
antibodies. Band intensities of Western blots were measured by densitometric analysis.
GAPDH bands were used as internal controls to correct for protein loadings.
RESULTS
Down-regulation of NS5A protein levels by ZnMP
Earlier studies from our and other laboratories have shown that heme or cobalt
protoporphyrin (CoPP) significantly reduced HCV20 or HBV26 core proteins. However,
little attention has been given to the effect of ZnMP on the HCV proteins. To investigate
whether ZnMP down-regulates the HCV proteins, we measured NS5A protein levels in 9–13
and Con1 cells, and core protein levels in CNS3 cells exposed to different concentrations of
ZnMP (0, 1, 5, 10 μM) for 4 h, ZnMP led to a marked decrease of NS5A protein levels in 9–
13 and Con1 cells in a dose-dependent fashion (Fig. 1A & B).
The effect was selective and specific: there were no detectable effects of ZnMP on HCV
core protein levels in CNS3 cells and in Huh-7/T7 cells transfected with pFK-Con1/GND, a
plasmid encoding a replication deficient variant of Con1 (Fig. 1C & D). We also observed
that protein levels were not affected by 10 μM free mesoporphyrin or ZnCl2 (Fig. 2A). Tin
mesoporphyrin (SnMP), another competitive HO inhibitor, has been reported recently to
down-regulate Bach1 protein levels and induce the HO-1 gene expression in NIH 3T3 cells.
We thus performed comparative studies on ZnMP vs SnMP down-regulation of NS5A in 9–
13 cells. As shown in Fig. 2B, ZnMP markedly and rapidly decreased NS5A protein levels
after exposure to ZnMP for as little as 2 h. In contrast, no detectable effects of SnMP on
NS5A protein levels were observed. In addition, the potent zinc chelator, N, N, N, N-
tetrakis-(2-pyridylmethyl) ethylenediamine (TEPN) did not affect ZnMP-mediated profound
down-regulation of NS5A protein levels in 9–13 cells (Fig. 3).
ZnMP decreases the stability of NS5A protein
Next we examined whether down-regulation of NS5A protein by ZnMP occurs at a post-
translational level. As shown in Fig. 4, NS5A protein levels in 9–13 cells treated with ZnMP
and cycloheximide (CHX) were greatly and rapidly reduced. NS5A protein levels in 9–13
cells that were not treated with ZnMP were also decreased by CHX, but to a much lesser
extent. Specifically, ZnMP at a concentration of 10 μM decreased the NS5A protein half life
(t1/2) from 18.7 h to 2.7 h (Fig. 4B & C).
Proteasome inhibitors abrogate the degradation of NS5A by ZnMP
To understand whether degradation of NS5A protein by ZnMP is proteasome dependent, 9–
13 cells were treated with ZnMP (5, 10 μM) and selected proteasome inhibitors, epoxomicin
(5, 10 μM) and MG132 (10, 20 μM). We found that epoxomicin (5, 10 μM) and MG132 (10,
20 μM) completely abrogated the degradation of NS5A in cells exposed to a lower
concentration of ZnMP (5 μM), and cells treated with ZnMP (10 μM) and epoxomicin (5, 10
μM) or MG132 (10, 20 μM) displayed significant, although less than complete, diminution
of the degradation of NS5A by ZnMP (Fig. 5A & B), however, epoxomicin or MG132 did
not affect NS5A protein levels in the absence of ZnMP in 9–13 cells (Fig. 5C), suggesting
that the proteasome-dependent degradation pathway is involved in ZnMP-mediated NS5A
breakdown. The highest concentration of epoxomicin used in these experiments was 10 μM,
because cells exposed to 20 μM epoxomicin failed to grow well, indicating that this
concentration of epoxomicin was toxic to the cells.
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ZnMP induces polyubiquitination of NS5A protein
To gain insight into the mechanism by which ZnMP mediates degradation of NS5A protein,
we examined whether ZnMP induce polyubiquitination of NS5A [(Ub)n-NS5A]. After
treating cells with ZnMP, or with vehicle (DMSO) alone as control, cell lysates were
prepared and were subjected to immunoprecipitation (IP) of NS5A with anti-NS5A
monoclonal antibody. An immunoblotting (IB) analysis of the precipitates with an anti-
ubiquitin antibody revealed polyubiquitination of NS5A [(Ub)n-NS5A] following ZnMP
treatment (Fig. 6B). In contrast, it did not show a significant level of ubiquitination under
control condition (Fig. 6B). Immunoblot analysis with anti-NS5A antibody confirmed that
NS5A proteins were immunoprecipitated (Fig. 6C) and that higher-molecular-weight bands
may represent ubiquitylated forms of the NS5A protein (Fig. 6C). The results suggest that
ZnMP induce polyubiquitination of NS5A which contributes to the degradation of NS5A by
ZnMP.
ZnMP displays anti-viral activity
To evaluate whether ZnMP-mediated degradation of NS5A may play a role in inhibiting
HCV replication, Con1 full-length HCV replicon cells were treated with different
concentrations of ZnMP for 24 h. As expected, vehicle (DMSO) alone did not alter the
amounts of HCV replicon RNA, whereas treatment with ZnMP resulted in a dose-dependent
reduction in viral RNA (Fig. 7A), and protein levels (Fig. 7B), suggesting that ZnMP-
mediated rapid degradation of NS5A may lead to reduction of HCV RNA replication, and
subsequent decrease in HCV protein expression. And then we asked if NS5A is an actual
target of ZnMP and the effects of ZnMP on HCV RNA replication and core protein levels
are secondary to ZnMP-mediated rapid degradation of NS5A. To this end, we performed
parallel experiments with HCV proteins expressed from a DNA plasmid pFK-Con1/GND in
Huh-7/T7 cells, where their expression would not be linked to viral RNA polymerase but
only to T7 RNA polymerase. ZnMP markedly decreased NS5A protein levels in a dose-
dependent fashion, whereas HCV core protein levels remained unaffected after 24 h of
ZnMP treatment (Fig. 7C). We further observed that ZnMP resulted in reduction of core in
the system that HCV proteins were expressed from pFK-Con1/GDD in Huh-7/T7 cells,
where their expression would be partly linked to viral RNA polymerase (Fig. 7D), however,
the reduction of core was much less than the effect in Con1 replicon system, where
expression of HCV proteins were linked to viral RNA polymerase.
Next, we used the JFH1-based HCV cell culture system to investigate whether ZnMP down-
regulates NS5A protein and displays anti-viral activity in this novel JFH1-based (genotype
2a) HCVcc system. We measured NS5A and core protein levels in J6/JFH1 transfected
Huh-7.5 cells treated with indicated concentrations of ZnMP for 4 or 24 h. ZnMP led to a
rapid and profound decrease of NS5A protein levels, while core protein levels were not
affected after 4 h of ZnMP treatment and showed a decrease after 24 h exposure to ZnMP
(Fig. 8A-D). To further examine whether ZnMP inhibits HCV RNA replication/infection in
J6/JFH1 transfected and infected cell culture system, we analyzed HCV RNA expression
after ZnMP treatment. 10 μM of ZnMP markedly decreased HCV RNA levels by ~70% in
HCV-transfected cells and ~90% in HCV-infected cells (Fig. 8E & F).
To exclude the possibility that the reduction in HCV viral replication could be a non-specific
effect of ZnMP to cause cytotoxicity of treated cells, cells were exposed to ZnMP (0, 1, 5,
10 μM) for 2, 6, or 24 h. As shown in Suppl. Fig. 2, ZnMP treatments did not significantly
affect cell viability, suggesting that the effects of ZnMP on HCV viral RNA and protein
expression were not due to cytotoxic effects.
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The major findings of this paper are as follows: 1) ZnMP, but not the free mesoporphyrin
nor ZnCI2 down-regulates NS5A protein levels in a dose–dependent fashion in human
hepatoma cells stably expressing HCV proteins (Fig. 1, 2 & 3); 2) ZnMP reduces the
stability of NS5A protein by decreasing its half life from 18.7 h to 2.7 h, suggesting that the
effect of ZnMP on NS5A occurs at a post-translational level (Fig. 4); 3) proteasome
inhibitors, epoxomicin and MG132, block the degradation of NS5A (Fig. 5), indicating that
down-regulation of NS5A by ZnMP is proteasome dependent; 4) ZnMP significantly
induces polyubiquitination of NS5A, supporting the hypothesis that the proteasome-
ubiquitin degradation pathway is involved in down-regulation of NS5A (Fig. 6); 5) ZnMP
significantly reduces HCV RNA replication in Con1 replicon cells, JFH1-based HCV
transfected cells, and JFH1-based HCV infected cells, suggesting that ZnMP-mediated
degradation of NS5A may play a part in inhibiting HCV replication/infection (Fig. 7 & 8).
6) There is no evidence that ZnMP affects HCV core protein levels in CNS3 cells (Fig. 1C),
in Huh-7/T7 cells transfected with pFK-Con1/GND (Fig. 1D & 7C), a plasmid encoding a
replication deficient variant of Con1 (Fig. 1D), indicating that the effect of ZnMP on NS5A
is selective and specific.
In this study, three different cell lines that stably express HCV proteins and JFH1-based
HCV cell culture system were used (Suppl. Fig. 1). ZnMP decreased NS5A protein levels in
Con1-based replicon cells and JFH1-based HCV cell culture system but did not show
significant down-regulation of core protein in CNS3 (Fig. 1) and Huh-7/T7 cells transfected
with pFK-Con1/GND (Fig.1D & 7C). ZnMP at concentrations of 10 μM was not toxic
(Suppl. Fig. 2) and the maximal concentration of ZnMP used in this study was at 10 μM.
Therefore it is clear that the down-regulation of ZnMP on NS5A and HCV RNA repliction
are not due to a general, non-specific toxic effect, but due to its ability to activate the
ubiquitin-proteasomal pathway of NS5A protein catabolism.
In recent years, it has become increasingly clear that that NS5A plays a key role in HCV
RNA replication by participating in polyprotein cleavage, interferon response and cellular
signaling pathways8, 14. HCV NS5A includes domain I (amino acids 1–213), domain II
(amino acids 250–342), and domain III (amino acids 355–447)8, 27. The N-terminal domain
(domain I) contains a zinc binding motif, which is a vital component of the HCV
replication7. Domain II, containing an interferon sensitivity-determining region (amino
acids 237–276), is associated with IFN resistance and lack of response to treatment in
genotype1a-infected patients28. In this report, we observed that ZnMP induces markedly
down-regulation of NS5A without affecting core protein and significantly reduces HCV
RNA replication. We thus propose that the reduction of HCV RNA replication occurs
primarily through controlling the amount of HCV NS5A protein by ZnMP. These results
also provide strong evidence to support the novel strategy for treatment of HCV infection by
targeting NS5A protein levels.
Ubiquitin (Ub) was first identified as a highly-conserved small protein in eukaryotic cells
that is composed of 76 amino acids with a predicted molecular weight of 8.5 kDa29, 30. The
ubiquitin-proteasome degradation pathway has been well accepted as an important
regulatory system in many cellular processes such as cell cycle, DNA repair, embryogenesis,
the regulation of transcription and apoptosis29–31. In the ubiquitin-proteasome pathway,
protein substrates are first marked for degradation by covalent linkage to multiple molecules
of ubiquitin (polyubiquitination) and then are hydrolyzed by the 26 S proteasome, a 2000
kDa ATP-dependent proteolytic complex. We previously reported that ZnMP produces
profound degradation of Bach1 protein in a proteasome-dependent manner as one of
molecular mechanisms by which ZnMP up-regulates the HO-1 gene expression17. Others
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have reported that HCV proteins, such as NS5B32, core33, 34, the unglycosylated cytosolic
form of E235, NS236, and F protein37 are degraded through the ubiquitin-proteasome
pathway. To our knowledge, the present study is the first report showing the degradation of
NS5A protein and reduction of HCV RNA replication by degradation of NS5A. Taken
together, these studies suggest that the ubiquitin-proteasome pathway plays a role in the
HCV life cycle or viral pathogenesis. In addition, our data provide a rationale to develop
antiviral drugs that increases ubiquitination of NS5A.
ZnMP induces polyubiquitination of NS5A and display anti-viral activity, we found ZnMP
an attractive choice, and we chose to use mainly ZnMP because of the profound effects on
Bach117, because mesoporphyrin derivatives lack reactive vinyl groups and are therefore
more chemically stable than protoporphyrin derivatives38, and because it is taken up by
intact liver cells far better than other zinc derivatives such as bisglycol-deuteroporphyrin
congener39. Zinc porphyrins, under some circumstances, may be toxic to hematopoietic cells
in vitro40. There was nothing to suggest cytotoxicity to liver cells in this work (Suppl. Fig.
2). In addition, earlier work showed no evidence of toxicity of intravenously administrated
ZnMP in intact rats. The ZnMP in these animals partitioned mainly to liver and spleen and
inhibited heme oxygenase activity particularly in these organs. In this study, we chose to
administer ZnMP bound to human serum albumin (HSA), because like other
metalloporphyrins, ZnMP has limited solubility in physiologic buffer, but its solubility and
uptake into liver cells are greatly enhanced by albumin binding41, 42 and because ZnMP,
when administered as an albumin complex, is nontoxic and is taken up preferentially by the
liver and spleen43.
In conclusion, we have found that ZnMP, but not the free mesoporphyrin nor the metallic
ion itself induces post-translational down-regulation of HCV NS5A protein in an ubiquitin-
proteasome degradation pathway. Our results indicate that ZnMP significantly suppresses
HCV viral replication in the Con1 full length replicon Huh-7.5 cells and JFH1-based HCV
cell culture system, suggesting that ZnMP may hold promise as a novel agent to treat HCV
infection. We propose that ZnMP-mediated ubiquitin-proteasome degradation pathway may
play a role in affecting the HCV RNA replication through controlling the amount of NS5A
protein. Our studies also raise many important new questions that need to be answered in
future. Further studies are underway in our laboratory, designed to unravel the molecular
mechanism that underlies the effect of ZnMP to trigger ubiquitination of Bach1 or HCV
NS5A, as well as to search for other zinc derivatives, which might display greater effects on
NS5A degradation and HCV RNA replication.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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JFH1 Japanese fulminant hepatitis 1
NS5A Nonstructural protein 5a of HCV
NTR non-translated region
PVDF Polyvinylidene fluoride
qRT-PCR Quantitative real time polymerase chain reaction
SDS Sodium dodecyl sulfate
SnMP Tin mesoporphyrin
TEPN N, N, N, N-tetrakis-(2-pyridylmethyl) ethylenediamine
ZnMP Zinc mesoporphyrin
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Figure 1. Dose-dependent down-regulation of HCV NS5A but not HCV core protein by ZnMP
Cells were treated with different concentrations of ZnMP (0, 1, 5, 10 μM) for 4 hours, after
which cells were harvested and total proteins were isolated for Western blot analysis. The
bar graphs show quantitative results. The amounts of NS5A or core protein levels were
normalized to GAPDH which did not vary with treatment. Values for cells treated with
vehicle only were set equal to 1. Data are presented as means ± SE from triplicate samples. *
differs from vehicle only, P<0.05. (A) ZnMP decreased NS5A protein levels in 9–13 cells.
(B) ZnMP down-regulated NS5A protein levels in Con1 cells. (C) ZnMP did not alter core
protein levels in CNS3 cells. (D) ZnMP decreased NS5A protein levels, whereas HCV core
protein levels remained unchanged in Huh-7/T7 cells transfected with pFK-Con1/GND.
Huh-7/T7 cells, stably expressing the T7 RNA polymerase, were transfected with 0.8 ug/
well of pFK-Con1/GND by Lipofectamine and Plus Reagent. 48 h after transfection, cells
were treated with ZnMP (0, 1, 5, 10 μM) for 4 h. The levels of HCV NS5A, core and
GAPDH protein were measured by Western blots.
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Figure 2. Specificity of ZnMP-mediated down-regulation of NS5A protein levels
(A) 9–13 cells were exposed to ZnMP, free mesoporphyrin (Meso) or ZnCl2 (all at 10 μM)
for 4 hours. Western blot was performed using anti-HCV NS5A and GAPDH specific
antibodies. (B) 9–13 cells were treated with 10 μM ZnMP or with 10 μM SnMP for
indicated times (0, 2, 4, 6 h). The levels of HCV NS5A and GAPDH protein were measured
by Western blots. The bar graphs show quantitative results. The relative amounts of NS5A
protein levels were normalized to those for GAPDH, which did not vary with treatment.
Values for cells treated with vehicle only were set equal to 1. Data are presented as means ±
SE from triplicate samples. * differs from vehicle only, P<0.05.
Hou et al. Page 12













Figure 3. Effect of zinc chelator on NS5A protein levels in 9–13 cells
9–13 cells were treated with indicated concentrations of TEPN 30 min before ZnMP
treatment, the cells were subsequently exposed to ZnMP or to vehicle (DMSO) alone as
control for 4 h. NS5A and GAPDH protein levels were measured by Western blot. The bar
graphs show quantitative results. The relative amounts of NS5A protein were normalized to
those for GAPDH, which did not vary with treatment. The band intensity of NS5A from
vehicle alone was set equal to 1. * differs from vehicle only, P<0.05.
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Figure 4. ZnMP-induced degradation of NS5A in 9–13 cells
(A) 9–13 cells were treated with 100 ug/mL cycloheximide (CHX) and with or without 10
μM ZnMP for the indicated periods (0, 1, 2, 4, 8, 24, 36, 48 h), and then cells were harvested
and total proteins were isolated. NS5A or GAPDH protein levels were measured by Western
blot. (B) The intensities of bands in panel A were quantified by densitometry. The band
intensity of NS5A from sample (0 h) was set at 1. (C) Half-lives of NS5A protein in the
absence (triangles) or presence (squares) of ZnMP.
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Figure 5. ZnMP down-regulates NS5A by a proteasome-dependent process
9–13 cells were treated with indicated concentrations of MG132 or epoxomicin 30 min
before ZnMP treatment, the cells were subsequently exposed to ZnMP (5, 10 μM) or to
vehicle alone (0 μM) as control for 4 h. NS5A and GAPDH protein levels were measured by
Western blot. (A) NS5A protein levels in 9–13 cells treated with ZnMP (5, 10 μM) and
different concentrations of epoxomicin (5, 10 μM) or MG132 (10, 20 μM). (B) The
intensities of bands in panel A were quantified by densitometry. The amounts of NS5A
protein were normalized to those for GAPDH, which did not vary with treatment. The band
intensity of NS5A from vehicle alone was set equal to 1. * differs from vehicle only,
P<0.05. (C) NS5A protein levels in 9–13 cells exposed to epoxomicin or MG132 in the
absence of ZnMP.
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Figure 6. ZnMP-induced ubiquitination of NS5A
9–13 cells were treated without or with 10 μM ZnMP for 4 h. Total proteins were extracted
for subsequent Western blot or immunoprecipitation analysis. Immunoprecipitation was
carried out using anti-HCV NS5A antibody. Ubiquitin conjugation of NS5A
[polyubiquitinated NS5A (Ub)n-NS5A] was examined with immunoprecipitation using an
anti-HCV NS5A antibody and immunoblot using an anti-ubiquitin antibody. (A) Western
blot analysis of NS5A protein levels before immunoprecipitation shows down-regulation of
NS5A by ZnMP. (B) Ubiquitination of NS5A following ZnMP treatment, or vehicle
(DMSO) only was compared. The positions of molecular mass markers (in kilodaltons) are
indicated to the left of the gel. The bracket indicates polyubiquitinated NS5A. Asterisks
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indicate cross-reacting immunoglobulin heavy chain. (C) Immunoblot analysis with an anti-
NS5A antibody indicates that NS5A proteins were immunoprecipitated in panel B. The
bracket indicates lower-mobility bands containing NS5A. These bands may represent
polyubiquitinated NS5A.
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Figure 7. Down-regulation of HCV RNA and protein expression by ZnMP
Con1 cells were treated with indicated concentrations of ZnMP, or DMSO as control. After
24 h, cells were harvested and total RNA and proteins were extracted. HCV virus RNA was
quantified by qRT-PCR, and the levels of HCV core, NS5A and GAPDH protein were
measured by Western blots. Data are presented as means ± SE, n=3. * differs from vehicle
only (ZnMP, 0 μM), P<0.05. (A) Effect of ZnMP on HCV RNA replication. (B) Effect of
ZnMP on HCV core and NS5A protein levels. The upper panel shows photographs of
representative Western blots. The bar graph shows quantitative results. (C) Down-regulation
of HCV NS5A but not core by ZnMP in Huh-7/T7 cells transfected with pFK-Con1/GND.
Huh-7/T7 cells were transfected with 0.8 ug/well of pFK-Con1/GND. 48 h after
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transfection, cells were treated with ZnMP (0, 1, 5, 10 μM) for 24 h. Cells were harvested
and total proteins were extracted for Western blots. (D) Effects of ZnMP on HCV core and
NS5A proteins in Huh-7/T7 cells transfected with pFK-Con1/GDD. Huh-7/T7 cells were
transfected with 0.8 ug/well of pFK-Con1/GDD. 48 h after transfection, cells were treated
with ZnMP (0, 1, 5, 10 μM) for 24 h. The levels of HCV NS5A, core and GAPDH protein
were measured by Western blots.
Hou et al. Page 20













Hou et al. Page 21













Figure 8. ZnMP down-regulates NS5A protein and display antiviral activity in the JFH1-based
HCV cell culture system
Huh-7.5 cells were transfected with 2 μg/well of J6/JFH1 RNA by Lipofectamine 2000.
After 48 h, cells were treated with indicated concentrations of ZnMP, or DMSO as control
for 4 or 24 h. HCV RNA was quantified by qRT-PCR, and HCV core, NS5A and GAPDH
protein levels were measured by Western blots. Data are presented as means ± SE, n=3. *
differs from vehicle only (ZnMP, 0 μM), P<0.05. (A) Effects of ZnMP on NS5A and core
protein levels following 4 h of ZnMP treatment. (B) The intensities of bands in panel A were
quantified by densitometry. (C) Effects of ZnMP on NS5A and core protein levels following
24 h of ZnMP treatment. (D) The intensities of bands in panel C were quantified by
densitometry. (E) Down-regulation of HCV RNA by ZnMP in Huh-7.5 cells transfected
with J6/JFH1 RNA. (F) Effects of ZnMP on HCV RNA levels in Huh-7.5 cells infected with
J6/JFH1 HCV. Huh-7.5 cells were infected with cell culture supernatants collected from the
cells transfected with HCV RNA, and treated with ZnMP or DMSO as control for 48 h.
HCV virus RNA was quantified by qRT-PCR, and the levels of HCV core, NS5A and
GAPDH mRNA were measured by qRT-PCR.
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